Signal: Roche to refile subcutaneous Tecentriq with FDA after UK approval
Roche planned to launch its new subcutaneous Tecentriq formulation this year, but it will be pushed back after tweaks requested by FDA.
Roche planned to launch its new subcutaneous Tecentriq formulation this year, but it will be pushed back after tweaks requested by FDA.
What's Your Reaction?
